Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Extrawell Pharmaceutical Holdings Limited ( (HK:0858) ) has shared an update.
Extrawell Pharmaceutical Holdings has announced board and committee changes effective 20 January 2026, with long-serving independent non-executive director (INED) Fang Lin Hu resigning from the board and from his roles as chairman of the audit and remuneration committees and member of the nomination committee, citing advanced age and a desire to focus on family. He leaves without any disputes with the board. The company has appointed private equity veteran Yang Xiaorong as a new INED, bringing extensive experience in risk management, governance frameworks, compliance and institutional process design, as well as a background in government-affiliated organizations in Shanghai, which is expected to strengthen the Group’s corporate governance and oversight capabilities; she will receive an annual director’s fee of HK$70,000 and will be subject to shareholder re-election in line with the company’s bye-laws.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.10 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
More about Extrawell Pharmaceutical Holdings Limited
Extrawell Pharmaceutical Holdings Limited is a Bermuda-incorporated company listed in Hong Kong, operating in the pharmaceutical sector through its group of subsidiaries. The Group focuses on the development, production and sale of pharmaceutical products, serving healthcare and medical markets primarily in Greater China.
Average Trading Volume: 2,394,590
Technical Sentiment Signal: Buy
Current Market Cap: HK$242.2M
For an in-depth examination of 0858 stock, go to TipRanks’ Overview page.